New Hope for Fibromyalgia Patients with Erik Lundquist, MD

Episode 66: Sponsored | New Hope for Fibromyalgia Patients with Erik Lundquist, MD

Fibromyalgia is a tricky disorder to treat. Patients struggle with chronic pain and fatigue, and practitioners often struggle to find effective interventions. Dr. Erik Lundquist is pioneering research into novel treatments for fibromyalgia. In a new study, he investigates the use of specialized pro-resolving lipid mediators (SPMs) for fibromyalgia patients.

Episode 62: Methionine Metabolism and Methylation with Dr. David Quig

Episode 62: Sponsored | Methionine Metabolism and Methylation with Dr. David Quig

Methylation and sulfuration are complex processes and assessing them in practice takes skill, knowledge, and consideration of multiple genes and other factors. Lucky for us, we have the incredible Dr. David Quig from Doctor’s Data on the podcast today, getting into the nitty-gritty about assessing methylation in clinical practice.

Episode 60: Dutch™ Research And Validation In Peer-reviewed Journal Article

Episode 60: Dutch™ Research and Validation In Peer-Reviewed Journal Article

In today’s podcast, I chat with my friend and fellow laboratory geek Mark Newman, founder and president of Precision Analytical (creators of DUTCH), about his recent publication [Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC–MS/MS)], smartly published in an open access – and reputable – journal, BMC Chemistry, so it’s available to all, free of charge.

Episode 58: SPONSORED - Biocidin - Borrelia Research and Clinical Strategies using Botanical Antimicrobials

Episode 58: SPONSORED Biocidin – Borrelia Research and Clinical Strategies using Botanical Antimicrobials

Lyme disease (and co-infections) can be tough to treat. The Lyme spirochete, Borrelia burgdorferi, has adopted loads of devilishly clever cloaking devices – from thriving in biofilm to existing in pleomorphic forms – to ensure survival despite aggressive treatment. Enter botanical therapy. With or without concurrent antibiotics, botanical combinations are an essential component of the FxMed clinician’s toolkit.

Advances in Stool Testing: The GI-MAP™ GI-Microbial Assay Plus with Tony Hoffman

Episode 56: SPONSORED Advances in Stool Testing: The GI-MAP™ GI-Microbial Assay Plus with Tony Hoffman

I had loads of fun taking a tour through the wonderment of DSL GI MAP test today with Tony Hoffman, CEO of DSL (and longtime friend of mine!). DSL’s GI MAP stool test is, as CEO Tony Hoffman states, “a clinician diagnostic tool,” not a microbiome test. Yes, of course the GI MAP looks at the microbiome, but it’s not a broad sweep of the myriad bugs taking up residence.

Episode 54: SPONSORED Non-Alcoholic Fatty Liver Disease: Dr. Robert Rountree shares his Expertise (and Powerpoint!)

Non-alcoholic fatty liver disease is an urgent, often unrecognized concern. It’s the hepatic pandemic of the 21stcentury, and there is NO approved pharmaceutical therapy (the race is on, however…). Fortunately for us, there is MUCH we can do in functional medicine – indeed, our toolkit is powerfully effective in turning around NAFLD and even NASH – the next step progression.

Episode 52: A Conversation with Dr. Joel Evans on KBMO Food Sensitivity Testing

Episode 53: Move From Biological Plausibility to Clinical Efficacy

Dr. Joel Evans – you probably know him as long-time IFM faculty teaching in the Advanced Practice Hormone Module. He’s also donned a newish hat as KBMO’s Medical Director. Dr. Evans loves the FIT test for delayed hypersensitivities to foods, and states that the addition of complement fragment C3d to their test significantly reduced the incidence of false positive results found on standard IgG testing.

Endotoxemia The Underlying Reason Most of Your Patients Need Immunoglobulins with Dr. Jill Carnahan

Episode 46: Endotoxemia: The Underlying Reason Most of Your Patients Need Immunoglobulins with Dr. Jill Carnahan

In my podcast with Dr. Jill Carnahan this month, she unleashes a torrent of compelling science and clinical savvy on all things endotoxemia. From heart disease and diabetes to autoimmunity (genetic or acquired) and mast cell activation, Dr. Carnahan is clear that pathological intestinal permeability (she discusses testing, but at this point in her career believes most everyone who sees her with chronic disease has IP) drives inflammation by allowing excess microbial endotoxins- primarily as lipopolysaccharide (LPS) – to enter circulation.